

# **Oncology Test Request**

<b>Client Information (requ</b>	uired)		<b>Patient Informa</b>	tion (required)				
Client Name			Patient ID (Medical Record No.)					
Client Account No.			Patient Name (Last, First, Middle)					
Client Phone Client Order No.		Sex			Birth Date (mm-dd-yyyy)			
Street Address			Collection Date (mm-dd-yyyy)		Time	□ am □ pm		
City	State	ZIP Code	Specimens Provided (required)			_		
Submitting Provider Information (required) Submitting/Referring Provider Name (Last, First)			☐ Blood ☐ Bone marrow	☐ Paraffin blo No. sent: _		☐ Tissue  No. sent:		
			☐ Fixed cells ☐ Cultured cells	Indicate sou		☐ Frozen ☐ Fixed formalin ☐ Wet tipeur		
Fill in only if Call Back is required.  Phone (with area code)  Fax* (with area code)		ea code)	☐ DNA☐ Lymph node☐ Spleen			☐ Wet tissue ☐ Other fixative Type:		
National Provider Identification (NPI)				☐ Slides No. sent: _				
*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.						Anatomic site:		
<b>Pathologist Informatio</b>	n (required)		CBC Results					
Submitting/Referring Pathologist Name (Last, First)		HB: HCT:			WBC: PLT:			
Phone (with area code) Fax* (with area code)		If ordering HER2 testing:  Was specimen fixed in 10% neutral buffered formalin within						
National Provider Identification (NPI)			1 hour of surgical collection time? ☐ Yes ☐ No Has specimen been fixed in 10% neutral buffered formalin for					
*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.			6 to 72 hours?					
<b>New York State Patients: Informed</b>	Consent for Genetic T	esting	Pathology/Clinic					
"I hereby confirm that informe individual legally authorized to or the individual's provider's or	do so and is on file		Include a brief history, per for referral.	rtinent laboratory resul	ts, suspec	ted diagnosis, and reason		
Signature  The state of the sta								
Note: It is the client's responsibility to	o maintain documentatio	on of the order.						
MCL Internal Use Only			ICD-10 Diagnosis Co	de				

800-447-6424 (US and Canada) 507-266-5490 (outside the US)

• Payment terms are net 30 days.

• An itemized invoice will be sent each month.

Call the Business Office with billing-related questions:

**Billing Information** 

 $\label{thm:condition} \textit{Visit www.MayoClinicLabs.com} \ \ \textit{for the most up-to-date test and shipping information}.$ 

Ship specimens to:

Mayo Clinic Laboratories

3050 Superior Drive NW

Rochester, MN 55905

**Customer Service: 800-533-1710** 

### **Patient Information (required)**

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

### **FEATURED ONCOLOGY TESTING**

PD-L1 Imm	unohistochemical stains
□ 22C3	Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual
□ 288PD	Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual
□ SP142	Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual
□ SP263	Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual
Microsatel	lite Instability (MSI)/Mismatch Repai
☐ TMSI	Microsatellite Instability, Tumor
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor
Pan-Cance	er Biomarkers
□ NTRK	NTRK Gene Fusion Panel, Tumor
□ NTRKM	NTRK Genes Mutation Analysis, Next-Generation Sequencing, Tumor
□ BRAFD	BRAF V600E/V600K Somatic Mutation Analysis, Tumor

Next-Gene	ration Sequencing (NGS) Panels
□ МСВРР	MayoComplete Bladder Prostate Panel
□ MCCRC	MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor
□ MCSRC	MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumo
☐ MCECP	MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumo
□ MCGST	MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor
□ MCGYN	MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumo
□ MCKCP	MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor
□ MCLNG	MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
☐ MCMLN	MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor
☐ MCSTP	MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor

Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor					
MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor					
MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor					
Sarcoma Targeted Gene Fusion/ Rearrangement Panel, Next-Generation Sequencing, Tumor					
Chromosomal Microarray					
Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded					
NA (cfDNA) Testing					
Cell-Free DNA BRAF V600, Blood					
Cell-Free DNA EGFR T790M Mutation Analysis, Blood					
Cell-Free DNA KRAS 12, 13, 61, 146, Blood					
MayoComplete Liquid Biopsy Panel, Next-Generation Sequencing, Cell-Free DNA					

#### **PATHOLOGY**

☐ PATHC Pathology Consultation Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis

#### **PATHOLOGY: TARGETED TUMOR TESTING**

#### **Bone and Soft Tissue**

Alveolar Rhabdomyosarcoma (ARMS), ☐ F0X0F 13q14 (F0X01 or FKHR) Rearrangement, FISH, Tissue

☐ TFE3F Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC), Xp11.23

(TFE3), FISH, Tissue

☐ MASF Angiosarcoma, MYC (8q24) Amplification,

FISH, Tissue

B-Catenin Mutations Analysis,  $\square$  CTNBT

Next-Generation Sequencing, Tumor

☐ DICET DICER1 Mutation Analysis, Next-Generation Sequencing, Tumor

ETV6 (12p13.2) Rearrangement, FISH, ☐ ETV6F

Endometrial Stromal Tumors (EST), 7p15 ☐ ESTUF

(JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE)

Rearrangement, FISH, Tissue

	Rearrangement, FISH, Tissue	
□ MYODT	MYOD1 Mutation Analysis, Next-Generation Sequencing, Tumor	
□ IMTF	Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH, Tissue	
□ FUSF	Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11.2 ( <i>FUS</i> or <i>TLS</i> ) Rearrangement, FISH, Tissue	
□ MDM2F	MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/ Atypical Lipomatous Tumor, FISH, Tissue	
□ DDITF	Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue	
□ PDGF	PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue	
□ SS18F	Synovial Sarcoma (SS), 18q11.2	

(SS18 or SYT) Rearrangement, FISH, Tissue

USP6 (17p13), Aneurysmal Bone Cyst

and Nodular Fasciitis, FISH, Tissue

Ewing Sarcoma (EWS), 22q12 (EWSR1)

☐ EWSF

☐ USPF

Breast	
□ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue
☐ BRCAT	BRCA1/2 Mutation Analysis, Next-Generation Sequencing, Tumor
☐ PIK3B	Cell-Free DNA PIK3CA Test, Blood
□ ESR1T	ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor
☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue
☐ H2BR	HER2 Amplification Associated with Breast Cancer, FISH, Tissue
□ ESR1T	ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue
☐ PIK3T	PIK3CA Mutation Analysis, Tumor
	tochemical assays interpreted image analysis
□ ERPR	Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual
☐ KI67B	Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
□ HERBA	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex

## **Patient Information** (required)

☐ MCGYN MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

Dil til Date	(IIIIII-uu-yyyy)					
Gastrointe	etinal	□ MCECP	MayoComplete Endometrial Carcinoma	] [	□ MGMT	MGMT Promoter Methylation, Tumor
□ BRAFD BRAF V600E/V600K Somatic Mutation		I WICLUF	Panel, Next-Generation Sequencing, Tumor		□ NONCP	Neuro-Oncology Expanded Panel with
	Analysis, Tumor	☐ ML1HM MLH1 Hypermethylation Analysis, Tumor				Rearrangement, Tumor
□ EGFRS	EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor	□ POLET	POLE Mutation Analysis, Next-Generation Sequencing, Tumor		☐ TERTT	TERT Promoter Mutations, Next-Generation Sequencing, Tumor
□ PRKAF	Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue	Ovarian Car	rcinoma FOXL2 Mutations Analysis, Next-Generation		☐ TP53	TP53 Mutation Analysis, Next-Generation Sequencing, Tumor
☐ FGFR2	FGFR2 (10q26.1) Rearrangement, FISH,	\ LEI	Sequencing, Tumor	li	Pulmonary	
☐ H2GE	Tissue HER2 Amplification Associated with	□ MCOCP	MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel,		□ ALKT	ALK Mutation Analysis, Next-Generation Sequencing, Tumor
	Gastroesophageal Cancer, FISH, Tissue		Next-Generation Sequencing, Tumor		□ BRAFD	BRAF V600E/V600K Somatic Mutation
☐ H2MT	HER2 Amplification, Miscellaneous Tumor, FISH, Tissue		-Genital Tract Carcinoma		_	Analysis, Tumor
☐ KINET	Ki-67(MIB-1), Gastrointestinal/Pancreatic	☐ HPVE6	Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization		□ EGFRS	EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
	Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated	☐ HPVHL	Human Papillomavirus (HPV) High/Low Risk, In Situ Hybridization		□ EGFRW	EGFR Targeted Mutation Analysis with ALK Reflex, Tumor
☐ METF	MET (7q31), FISH, Tissue	☐ HPVLR	Human Papillomavirus (HPV), Low-Risk,		☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue
☐ ML1HM	MLH1 Hypermethylation Analysis, Tumor		In Situ Hybridization		☐ KRASP	KRAS Somatic Mutation Analysis, Tumor
□ BRMLH	MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor	Head and I	Neck FGFR1 (8p11.2) Amplification, FISH, Tissue		□ LCAF	Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor	☐ HPVHL	Human Papillomavirus (HPV) High/Low Risk, In Situ Hybridization		☐ RETF	Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue
☐ TMSI	Microsatellite Instability, Tumor	☐ HPVE6	Human Papillomavirus (HPV) High-Risk		□ ROS1F	Lung Cancer, ROS1 (6q22) Rearrangement
Genitourin			E6/E7, RNA In Situ Hybridization			FISH, Tissue
☐ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC),	☐ HPVLR	Human Papillomavirus (HPV), Low-Risk, In Situ Hybridization		☐ MESOF	Mesothelioma, CDKN2A Fish, Tissue
	Xp11.23 (TFE3), FISH, Tissue	☐ MAMLF	MAML2 (11q21) Rearrangement,		☐ METF	MET (7q31), FISH, Tissue
☐ GCTF	Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue		Mucoepidermoid Carcinoma (MEC), FISH, Tissue			RY ONCOLOGY TESTING
☐ H2UR	HER2 Amplification Associated with	□ SGTF	MYB (6q23) Rearrangement, FISH, Tissue		☐ BAP1Z	BAP1-Tumor Predisposition Syndrome, BAP1 Full Gene Analysis
	Urothelial Carcinoma, FISH, Tissue	Melanoma			□ BHDZ	Birt-Hogg-Dube Syndrome, FLCN,
☐ MCKCP	MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor	□ BRAFB	Cell-Free DNA BRAF V600, Blood		_	Full Gene Analysis
☐ FUROC	UroVysion for Detection of Bladder Cancer,	☐ BRAFD	BRAF V600E/V600K Somatic Mutation Analysis, Tumor		☐ HB0CZ	BRCA1/BRCA2 Genes, Full Gene Analysis
	Urine	□ BRFKT	BRAF/KIT Mutation Analysis,		☐ BRGYP	Hereditary Breast/Gynecologic Cancer Pane
☐ MCBPP	MayoComplete Bladder Prostate Panel		Next-Generation Sequencing, Tumor		□ COMCP	Hereditary Common Cancer Panel
□ MCFRC	MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel,	Neuro-Oncology			□ CDHZ	Hereditary Diffuse Gastric Cancer Syndrome, <i>CDH1</i> , Full Gene Analysis
	Next-Generation Sequencing, Tumor	☐ GLIOF	1p/19q Deletion in Gliomas, FISH, Tissue		□ ENDCP	Hereditary Endocrine Cancer Panel
□ NUT1F	NUTM1 (15q14) Rearrangement, FISH, Tissue	☐ ALKT	ALK Mutation Analysis, Next-Generation Sequencing, Tumor		☐ XCP	Hereditary Expanded Cancer Panel
☐ TFEBF	Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue	□ BRAFD	BRAF V600E/V600K Somatic Mutation		□ CRCGP	Hereditary Gastrointestinal Cancer Panel
☐ SDHMP	SDH Genes Mutation Analysis,		Analysis, Tumor		□ LRCCZ	Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome, <i>FH</i> , Full Gene Analysis
	Next-Generation Sequencing, Tumor	☐ CMAPT	Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded		□ PANCP	Hereditary Pancreatic Cancer Panel
☐ TFH FH Mutation Analysis,  Next-Generation Sequencing, Tumor		□ GCTF	Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue		☐ HPGLP	Hereditary Paraganglioma/ Pheochromocytoma Panel
Gynecology		☐ HISGT	Histone Genes Mutation Analysis,		□ PRS8P	Hereditary Prostate Cancer Panel
Endometr'-	I/IItarina Carainama					
	II/Uterine Carcinoma Endometrial Stromal Tumors (EST)		Next-Generation Sequencing, Tumor		☐ RENCP	Hereditary Renal Cancer Panel
Endometria ☐ ESTUF	Il/Uterine Carcinoma Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue	□ IDHT	Next-Generation Sequencing, Tumor  IDH1/IDH2 Mutations Analysis, Next-Generation Sequencing, Tumor		□ RENCP □ THYRP	Hereditary Renal Cancer Panel Hereditary Thyroid Cancer Panel Hereditary Wilms Tumor Panel

Next-Generation Sequencing, Tumor

### **Patient Information** (required)

ation (required)							
Patient ID (Medical Record No.)			Client Account No.				
Patient Name (Last, First, Middle)				Client Order No.			
Birth Date	: (mm-dd-yyyy)						
☐ LYNCP	Lynch Syndrome Panel	□ HGH	Growth Horm	ione, Serum	☐ HIAA	5-Hydroxyindoleacetic Acid, 24 Hour, Urine	
□ RETZZ	Multiple Endocrine Neoplasia Type 2	□ LH	Luteinizing H	ormone (LH), Serum	□ NSE	Neuron-Specific Enolase, Serum	
□ NF1Z	Syndrome, <i>RET</i> , Full Gene Analysis  Neurofibromatosis Type 1, <i>NF1</i> ,	☐ MCRPL	Macroprolact Neuron-Spec	tin, Serum eific Enolase, Serum	☐ HPP☐ SERU	Pancreatic Polypeptide, Plasma Serotonin, 24 Hour, Urine	
☐ PTNZ	Full Gene Analysis PTEN Hamartoma Tumor Syndrome,	□ PLPMA	-	uitary Macroadenoma, Serum	□ SERWB	Serotonin, Blood	
	PTEN Full Gene Analysis	□ PRL	Prolactin, Se	rum	□ VIP	Vasoactive Intestinal Polypeptide, Plasma	
☐ STK1Z	Peutz-Jeghers Syndrome, <i>STK11</i> , Full Gene Analysis	Biogenic A		ne Fractionation, Free,	Genitourina  AFPSF	Ary Alpha-Fetoprotein (AFP), Spinal Fluid	
☐ BRTP	Rapid Hereditary Breast Cancer Treatment Decision Panel		24 Hour, Urin	e	□ AFP	Alpha-Fetoprotein (AFP) Tumor Marker,	
□ UGTFG	UDP-Glucuronosyltransferase 1A1	☐ CATP		ne Fractionation, Free, Plasma Acid, 24 Hour, Urine	□ BHCG	Serum  Beta-Human Chorionic Gonadotropin,	
_	(UGT1A1), Full Gene Sequencing	☐ HVAR	Homovanillic	Acid, Random, Urine		Quantitative, Serum	
□ U1A1Q	UDP-Glucuronosyltransferase 1A1 TA Repeat Genotype, UGT1A1	□ HIAA	5-Hydroxyind	doleacetic Acid, 24 Hour, Urine	□ BHSF	Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid	
□ VHLZZ	Von Hippel Lindau Syndrome, <i>VHL</i> , Full Gene Analysis	☐ METAF	•	es, Fractionated, 24 Hour, Urine es, Fractionated, Free, Plasma	□ CEASF	Carcinoembryonic Antigen (CEA), Spinal Fluid	
PRIMARY	BODY FLUID TESTS	□ METRN		es, Fractionated, Random, Urine	□ PSA	Prostate-Specific Antigen (PSA) Diagnostic,	
TESTS FO	R DISEASE MONITORING	□ SERU	Serotonin, 24	Hour, Urine		Serum	
	IN THE DIAGNOSIS	☐ SERWB	Serotonin, Bl		□ SPSA	Prostate-Specific Antigen (PSA) Screen, Serum	
Bone and Soft Tissue ☐ IFG23 Intact Fibroblast Growth Factor 23, Serum		□ VH	Vanillylmandelic Acid and Homovanillic Acid, Random, Urine		□ PHI11	Prostate Health Index Reflex, Serum	
Breast		□ VMA	Vanillylmand	elic Acid, 24 Hour, Urine	☐ PSAFT	Prostate-Specific Antigen (PSA), Total and Free, Serum	
□ C2729	C2729 Breast Carcinoma-Associated Antigen,		Vanillylmand	elic Acid, Random, Urine	Gynecology		
_	Serum	Gastrointe	stinal		□ BHCG	Beta-Human Chorionic Gonadotropin,	
□ CA153	Cancer Antigen 15-3 (CA 15-3), Serum	☐ L3AFP		otein (AFP) L3% and Total,		Quantitative, Serum	
Endocrine Thyroid Car			Hepatocellular Carcinoma Tumor Marker, Serum		☐ CA25	Cancer Antigen 125 (CA 125), Serum	
□ CATLN	Calcitonin, Fine-Needle Aspiration Biopsy	☐ AFPPT	Alpha-Fetopr	otein (AFP), Peritoneal Fluid	☐ HE4	Human Epididymis Protein 4, Serum	
L CAILN	(FNAB)-Needle Wash, Lymph Node	☐ AFP	Alpha-Fetopr	otein (AFP) Tumor Marker,	□ INHA	Inhibin A, Tumor Marker, Serum	
☐ CATN	Calcitonin, Serum		Serum		☐ INHAB	Inhibin A and B, Tumor Marker, Serum	
□ CEA	Carcinoembryonic Antigen (CEA), Serum	☐ AMLPC		ncreatic Cyst Fluid	□ INHB	Inhibin B, Serum	
□ TGMS	Thyroglobulin Mass Spectrometry, Serum	☐ 199PC	Carbohydrate Pancreatic C	e Antigen 19-9 (CA 19-9), yst Fluid	□ ROMA	ROMA Score (Ovarian Malignancy Risk Algorithm), Serum	
☐ TFNAB	Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash	□ 199PT	Carbohydrate Peritoneal Fli	e Antigen 19-9 (CA 19-9),	Pulmonary		
☐ HTGR	Thyroglobulin, Tumor Marker Reflex, Serum	□ CA19	Carbohydrate	e Antigen 19-9 (CA 19-9),	☐ PF199	Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid	
☐ HTG2	Thyroglobulin, Tumor Marker, Serum		Serum		☐ PFCEA	Carcinoembryonic Antigen (CEA),	
Neuroendo □ CGAK			Pancreatic C	ryonic Antigen (CEA),		Pleural Fluid	
☐ GAST	Gastrin, Serum	☐ CEAPT			□ NSE	Neuron-Specific Enolase (NSE), Serum	
□ GLP	Glucagon, Plasma		Peritoneal Flu	uid	ADDITION		
□ NSE	Neuron-Specific Enolase, Serum	□ CEA	Carcinoembr	yonic Antigen (CEA), Serum	(INDICATE	TEST CODE AND NAME)	
☐ HPP	Pancreatic Polypeptide, Plasma	□ CGAK	Chromograni	n A, Serum			
□ VIP	Vasoactive Intestinal Polypeptide, Plasma	□ DCP	Des-Gamma	-Carboxy Prothrombin, Serum			
Pituitary Tumors		□ F0BT		Blood, Colorectal Cancer itative, Immunochemical, Feces			
☐ ACTH	Adrenocorticotropic Hormone, Plasma	□ GAST	Gastrin, Seru				
□ APGH	Alpha-Subunit Pituitary Tumor Marker, Serum	□ GLP	Glucagon, Pla				
□ FSH	Follicle-Stimulating Hormone (FSH), Serum	☐ HCCGS	Hepatocellula GALAD Score	ar Carcinoma Risk Panel with b. Serum			